Drug intelligence / Profile preview

GHB11L1

Development stage: Phase 2
Lead developer: Baxter Healthcare Corporation
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

GHB11L1 is a replication-deficient live attenuated influenza vaccine (LAIV) developed by AVIR Green Hills Biotechnology for the prevention of influenza A (H1N1) infection. It is based on the deltaFLU platform, which utilizes a virus with a deleted NS1 (non-structural protein 1) gene. NS1 normally functions as the virus's primary defense against the host's interferon-mediated immune response; its deletion renders the vaccine virus replication-deficient while enhancing its ability to stimulate a broad immune response. The vaccine is administered as a single-dose liquid nasal spray and is designed to induce immunity against viral surface proteins.

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on GHB11L1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GHB11L1.

Explore the full profile